Data to be presented on potential benefits for EnteraGam® (Serum-derived bovine immunoglobulin/protein isolate, SBI)
FOR IMMEDIATE RELEASE
Entera Health, Inc. today announces three poster presentations that will take place at the Digestive Disease Week 2015 Annual Meeting in Washington, D.C., from Saturday, May 16th – Tuesday, May 19th, 2015.
Poster ID: SU1177
Sunday, May 17th, 2015 (12:00 PM – 2:00 PM)
Efficacy of Serum-derived Bovine Immunoglobulin/Protein Isolate (SBI) in Pediatric Patient with Acute Diarrhea Due to Small Intestinal Bacteria Overgrowth. Thomas L. Taxman, MD, The Institute For Women's & Children's Health, Beachwood, OH
Poster ID: Mo1708
Monday, May 18th, 2015 (12:00 PM – 2:00 PM)
Improved Tryptophan Metabolism and Decreased Inflammation Following Administration of Serum-Derived Bovine Immunoglobulin Isolate in a Mouse Model of IBD. Christopher J Detzel, PhD, Entera Health, Ankeny, IA
Poster ID: Tu2011
Tuesday, May 19th, 2015 (12:00 PM – 2:00 PM)
Resolution of Antibiotic-Induced and Idiopathic Diarrhea in Infants with a Serum-Derived Bovine Immunoglobulin Preparation. Manisha Dave, MD, Texas Digestive Disease Consultants, Plano, TX
EnteraGam® is a prescription medical food product intended to provide for distinctive nutritional requirements that are unique for the clinical dietary management of specific intestinal disorders [e.g., in irritable bowel syndrome with diarrhea (IBS-D), inflammatory bowel disease (IBD), and HIV associated enteropathy]. EnteraGam® is required to be used under physician supervision as part of ongoing medical care for a specific condition or disease. EnteraGam® is also indicated for the clinical dietary management of enteropathy in patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients. For full prescribing information, please visit our product website at http://enteragam.com/.
Important Safety Information
EnteraGam® is a specially formulated protein source for the management of intestinal disorders. The product has been extremely well tolerated for up to a year in HIV patients and up to 8 months in infants. The major side effects in clinical trials (2-5%) have included mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam® is contraindicated for patients with a hypersensitivity (allergy) to beef, or any components in EnteraGam®. Therefore, patients who have an allergy to beef or any component of EnteraGam® should not take this product. EnteraGam® has not been studied in pregnant or nursing mothers. The choice to administer EnteraGam® in pregnant or nursing mothers is at the clinical discretion of the physician. Medical foods like EnteraGam® are required by FDA regulations to be dosed and monitored by physicians as part of ongoing care for patients with chronic conditions or diseases.
About Entera Health, Inc.
Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. The staff's passion is to help people thrive through healthier living. The staff's motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Learn more at http://www.enterahealth.com/.
For information, please contact:
Tom Heck, Chief Operating Officer